| Vol.
02 Issue 04 Friday, March 21, 2008 |
|
|
|
|
Commercial
Scale
Antitubercular
Pyrazinamide
Isoniazid
Rifampicin
Antimalarial
Artesunate
Arteether
Artemether
Dihydroartemisinin
Macrolides
Azithromycin
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin oxime (intermediate)
Erythromycin phosphate
Erythromycin propionate
Erythromycin stearate
Roxithromycin
Antihypertensive
Lisinopril dihydrate
Losartan potassium
Antiepileptic
Sodium valproate
Valproic acid
Antiosteoporotic
Alendronate sodium
Zoledronic acid
Sedative, Hypnotic
Zopiclone
Antidepressant
Venlafaxine hydrochloride
Antihistaminic
Cetirizine dihydrochloride
Antithrombotic
Clopidogrel bisulphate
Pilot Plant Scale
Carvedilol
Clarithromycin
Pioglitazone hydrochloride
Rosiglitazone maleate
Valsartan
R & D Scale
Lumefantrine
Pamidronate disodium
Perindopril erbumine
Zolpidem tartrate
Development
Benazepril hydrochloride
Candesartan
Desvenlafaxine
Glipizide
Irbesartan
Levocetirizine
Ramipril
Rifabutin
Rifapentine
Risedronic acid
Telmisartan
Product
under patent offered only
for exempted research, clinical
and
development purposes.
Only non-
infrining products
and processes
are offered, subject to
patent status
verification by client. |
|
| Article
on the "Heralding Growth" of Calyx covered exclusively
in Express Pharma fortnightly issue, 1-15 March 2008 |
| Many
try to become jacks of all trades
and ultimately end up becoming master
of none. But Calyx Chemicals and
Pharmaceuticals with its strong focus has already become
a leading global supplier of anti-TB drugs. And they aim
to make their mark in the anti-malarial, anti-hypertensive
and anti-infective segments too. Suja Nair reports. |
Calyx
Chemicals and Pharmaceuticals has come a long way since
its inception in 1979. As an extension of finished
dosage company Alma Laboratories, the company is today
a US FDA, WHO (Geneva), European Directorate for the
Quality of Medicines (EDQM) approved, ISO 9001 and
14001 certified manufacturer of
intermediates and
Active Pharmaceutical Ingredients [APIs] with
an excellent custom synthesis capabilities. Calyx
is headquartered in Mumbai, with its
manufacturing and R&D facilities on the outskirts
of the city. |
 |
"As
an Oragnization we need to bring ourselves
in such a position that through
us the industry at large is also benefited."
-
Smitesh shah
Chairman
and Managing Director
Calyx
|
|
|
The company started with world class flask
technology with five 20 litre flasks
and today have their presence in multiple
locations with huge multiple reactors of world standards.
It has grown from being a three member team to staff
strength of 580 people, of which almost one third are
in R&D with a minimum master’s degree
and PhDs. According to Smitesh Shah, Chairman and
Managing Director, Calyx, "As a company we have more
than 50 Confidential Disclosure Agreements (CDAs) signed
and are actively working with 25 of them on live
projects, from gram to ton quantities. Out
of the top ten innovator companies,
we work with at least four on an active basis world-wide.
We currently service leading drug discovery companies
around the world with their requirements for
contract manufacturing, custom synthesis and
collaborative R&D that include
Full Time Equivalent (FTE) as well as Fee-For-Service
(FFS) and bioanalytical services." The
multipurpose manufacturing plants have capabilities
to produce from grams to tons in compliance
with current Good Manufacturing Practice
(cGMP), United States Food and Drugs
Association (US FDA), World Health Organization
(WHO), European Directorate for the Quality of Medicines
(EDQM), ISO 9001:2000, ISO 14000:2004, HIS and Certificate
Of Suitability (COS) norms, while their global footprint
includes marketing and sales offices in US, Japan and
sourcing office in China.
Read
the full article. |
|
|
|
We
participated in ‘Mazda’s Marvel Pharma-Chem 2008’
Exhibition held on February 29th – March 2nd,
2008, at Nehru Centre, Worli, Mumbai, India.
|
|
|
|
|
Disclaimer:
"The information in this e-mail and any attachments is
confidential and may be legally privileged. It is intended solely
for the addressee or addressees. If you are not an intended recipient,
please delete the message and any attachments and
notify the sender of misdelivery. Any use or disclosure of the
contents of either is unauthorized and may be
unlawful. All liability for viruses is excluded to the
fullest extent permitted by law. Any views expressed
in this message are those of the individual sender, except where
the sender states them, with requisite authority, to be
those of the specific Calyx company." |
To
unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
“Meet
us at 'Chemspec India 2008’ at Bombay Exhibition Centre (NSE),
Goregaon (E), Mumbai,
India, from April 9-10, 2008, at Hall-1, Stand No: C 8”
“Meet
us at 'CPhI
Japan' at Tokyo Big Sight, Tokyo, Japan, from April 9th –
11th, 2008, at Booth J – 29”
|
|
